2 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Withdrawn 2 |
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Empyema Treated With tPA & DNAse tPA alone, tPA plus dornase - Empyema | Phase 3 | Withdrawn | Children's Mercy Hospital Kansas City | 2016-01-01 | 2016-01-28 | |
| Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) PTK 0796, Linezolid - Skin Structures and Soft Tissue Infections | Phase 3 | Withdrawn | Paratek Pharmaceuticals Inc | 2009-07-01 | 2012-05-09 |
Abscess (1) · Cellulitis (1) · Empyema (1) · Soft Tissue Infections (1)
Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Connective Tissue Diseases (1) · Skin Diseases, Infectious (1) · Skin and Connective Tissue Diseases (1)
7-dimethylamino-9-(2,2-dimethylpropyl)aminomethylcycline (1) · Linezolid (1) · Moxifloxacin (1)
Children's Mercy Hospital Kansas City (1) · Paratek Pharmaceuticals Inc (1)
United States (1)
Robert Arbeit, MD (1) · Shawn D St. Peter, MD (1)